155 results
Page 8 of 8
8-K
EX-99.1
3lmqg7m0dj
14 Nov 18
BioXcel Therapeutics Reports Positive Results from Study in Agitated Schizophrenia Patients Supporting BXCL501 Clinical Development
8:44am
8-K
EX-99.1
v5a w1xek
9 Nov 18
BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update
7:35am
8-K
EX-99.1
0rgj0 e5f0q
5 Nov 18
First-in-human Phase 1b / 2 combination trial of BXCL701 and pembrolizumab (Keytruda®) expected to initiate in 4Q 2018
4:30pm
8-K
EX-99.1
ipzch2q1a
30 Oct 18
BioXcel Therapeutics Provides Update on the Clinical Advancement of BXCL501 for the Acute Treatment of Agitation
8:15am
8-K
EX-99.1
k4btcxl fd676
8 Aug 18
BioXcel Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update
4:02pm
8-K
EX-99.1
ifpwy3x3v d58
24 Jul 18
DPP8/9 Inhibition - The Primary Mechanism of BioXcel Therapeutics’ Lead Immuno-Oncology Asset, BXCL701, Highlighted in Peer-Reviewed Journal
5:20pm
8-K
EX-99.1
c6ql2pk73zqq3bx8ff
27 Jun 18
BioXcel Therapeutics Reports Positive Results from Phase 1b Trial of Intravenously-dosed Dexmedetomidine Supporting BXCL501 Development
4:17pm
8-K
EX-99.1
llcq1ku6j
7 Jun 18
BioXcel Therapeutics Appoints Vincent J. O’Neill M.D., as Senior Vice President and Chief Medical Officer
4:01pm
8-K
EX-99.1
p5dqtf73nulr sw
17 May 18
BioXcel Therapeutics Announces Data Presentation at ASCO 2018 Annual Meeting
4:17pm
10-Q
i7mb2m9vx n5wx4ewf
14 May 18
Quarterly report
4:20pm
8-K
EX-99.1
xfbt9a7ltxug3i
14 May 18
BioXcel Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update
4:19pm
8-K
EX-99.1
dmz k5iubflq
26 Apr 18
BioXcel Therapeutics Announces Acceptance of Abstract at ASCO 2018 Annual Meeting
4:12pm